CD48 expression in T-lymphoblastic leukemia/lymphoma and mature T-cell neoplasms: role in detecting measurable residual disease and potential confounders, a single-institution retrospective review
American Journal of Clinical Pathology · 04.06.2026 · 165 (6)
DOI: 10.1093/ajcp/aqag060 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 10.06.2026. Verfasst von Alireza Torabi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, United States. Hauptthemen laut MEDLINE: Neoplasm, Residual, Biomarkers, Tumor, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, T-Cell. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Objectives
Assessing the stage of maturation is critical for the classification of T-cell neoplasms and is helpful in minimal/measurable residual disease (MRD) testing for T-lymphoblastic leukemia (T-ALL). This study analyzes the utility of CD48 in characterizing T-cell neoplasms at diagnosis and posttherapy.
Methods
This retrospective review characterizes the expression of CD48 in T-ALL and mature T-cell neoplasms at diagnosis and posttreatment. CD48 intensity was assessed qualitatively by flow cytometry relative to the background T cells. Potential confounders were also evaluated.
Results
T cells show increases in CD48 expression with progressive maturation, with high-level expression on mature T cells. CD48 expression by flow cytometry was decreased to absent (compared with expression on mature T cells) in 100% of T-ALL cases at diagnosis and in 92% of cases positive for MRD posttherapy. By contrast, among mature T-cell neoplasms, CD48 expression at diagnosis overlapped with expression on background mature T cells in most cases (91%). Reduced CD48 expression on background, nonneoplastic T cells was seen in the setting of alemtuzumab therapy and in samples with glycosylphosphatidylinositol (GPI)–deficient populations.
Conclusions
CD48 expression is diminished compared with normal background T cells in most cases of T-ALL at diagnosis and posttherapy, whereas it was typically retained in mature T-cell/natural killer–cell neoplasms. While CD48 levels may fluctuate after chemotherapy in T-ALL, reduced CD48 can be used as a marker of immaturity in most MRD cases. Potential confounders in the assessment of CD48 include alemtuzumab therapy and the presence of GPI-deficient populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, United States.
- Department of Pathology, University of Alabama, Birmingham, AL, United States.
Zitieren
APA
Torabi, A., Fromm, J. R., Dorer, R., Ding, Y., Glynn, E., Edlefsen, K. L., Shameli, A., Wu, D., & Cherian, S. (2026). CD48 expression in T-lymphoblastic leukemia/lymphoma and mature T-cell neoplasms: role in detecting measurable residual disease and potential confounders, a single-institution retrospective review. American Journal of Clinical Pathology, 165(6). https://doi.org/10.1093/ajcp/aqag060
Vancouver
Torabi A, Fromm JR, Dorer R, Ding Y, Glynn E, Edlefsen KL, et al. CD48 expression in T-lymphoblastic leukemia/lymphoma and mature T-cell neoplasms: role in detecting measurable residual disease and potential confounders, a single-institution retrospective review. American Journal of Clinical Pathology. 2026;165(6). doi:10.1093/ajcp/aqag060
BibTeX
@article{Torabi2026,
author = {Torabi, Alireza and Fromm, Jonathan R and Dorer, Russell and Ding, Yanna and Glynn, Emily and Edlefsen, Kerstin L and Shameli, Afshin and Wu, David and Cherian, Sindhu},
title = {CD48 expression in T-lymphoblastic leukemia/lymphoma and mature T-cell neoplasms: role in detecting measurable residual disease and potential confounders, a single-institution retrospective review},
journal = {American Journal of Clinical Pathology},
year = {2026},
volume = {165},
number = {6},
doi = {10.1093/ajcp/aqag060}
}
EUVIMED